Literature DB >> 9886300

High prevalence of low bone mass in thalassaemia major.

C E Jensen1, S M Tuck, J E Agnew, S Koneru, R W Morris, A Yardumian, E Prescott, A V Hoffbrand, B Wonke.   

Abstract

Cooley's original description of beta-thalassaemia major included marked bone deformities as a characteristic feature. These were thought to be due to expansion of haemopoiesis attempting to compensate for the congenital anaemia. Regular blood transfusions from infancy prevents these skeletal problems. Nevertheless, symptoms due to bone disease frequently occur in adult patients. Osteoporosis has not previously been reported as a cause of severe morbidity in thalassaemia major. The present study shows a high prevalence of low bone mass among thalassaemia major patients and analyses the predisposing causes. Bone density scans were performed in 82 patients with transfusion-dependent beta thalassaemia. Factors known to be associated with low bone mass such as gender, endocrine disorders and lifestyle activities, together with factors specific to the thalassaemia and its management, were included in a series of univariate analyses to ascertain any significant associations. 42 (51%) of the patients had severely low bone mass and a further 37 (45%) had low bone mass. The three factors showing a statistically significant association with severely low bone mass were male sex, 24/38 (63%) males had severely low bone mass, compared with 18/44 (41%) females, the lack of spontaneous puberty, 22/32 (69%) who required therapeutic induction of pubertal development had severely low bone mass, compared with 19/47 (40%) with spontaneous puberty and diabetes, 8/10 (80%) diabetic patients had severely low bone mass, compared with 23/56 (41%) with normal glucose tolerance. There was no association between the bone mineral density measurements and the haematological characteristics or treatment details of these patients. Severely low and low bone mass are common findings in patients with beta-thalassaemia major despite optimal transfusion and iron chelation. The associated features suggest that the severely low bone mass is due to endocrine abnormalities, in contrast to the haematological causes of bone disease characteristically seen in untreated thalassaemics.

Entities:  

Mesh:

Year:  1998        PMID: 9886300     DOI: 10.1046/j.1365-2141.1998.01108.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  40 in total

Review 1.  Endocrine complications of thalassemia.

Authors:  D Tiosano; Z Hochberg
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 4.256

2.  Bone status in a mouse model of genetic hemochromatosis.

Authors:  P Guggenbuhl; P Fergelot; M Doyard; H Libouban; M-P Roth; Y Gallois; G Chalès; O Loréal; D Chappard
Journal:  Osteoporos Int       Date:  2010-10-26       Impact factor: 4.507

3.  Bone disease in adult patients with β-thalassaemia major: a case-control study.

Authors:  Marina Baldini; Stella Forti; Alessandra Orsatti; Fabio Massimo Ulivieri; Lorena Airaghi; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Intern Emerg Med       Date:  2011-12-17       Impact factor: 3.397

4.  Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: a historical cohort study in Southern Iran.

Authors:  M Bordbar; H Bozorgi; F Saki; S Haghpanah; M Karimi; A Bazrafshan; O R Zekavat
Journal:  J Endocrinol Invest       Date:  2019-06-21       Impact factor: 4.256

5.  Comparative effectiveness of alendronate and zoledronic acid on bone mass improvement in transfusion-dependent thalassemia patients.

Authors:  Omid Reza Zekavat; Mohamadreza Bordbar; Sezaneh Haghpanah; Forough Saki; Asghar Bazrafshan; Haleh Bozorgi
Journal:  J Bone Miner Metab       Date:  2019-04-11       Impact factor: 2.626

6.  Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover.

Authors:  Ellen B Fung; Elliott P Vichinsky; Janet L Kwiatkowski; James Huang; Laura K Bachrach; Aenor J Sawyer; Babette S Zemel
Journal:  Bone       Date:  2011-04-05       Impact factor: 4.398

7.  Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis.

Authors:  A Lasco; N Morabito; A Gaudio; A Crisafulli; A Meo; G Denuzzo; N Frisina
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

8.  The Xmn1 polymorphic site 5' to the (G)gamma gene and its correlation to the (G)gamma:(A)gamma ratio, age at first blood transfusion and clinical features in beta-thalassemia patients from Western Iran.

Authors:  Hooshang Nemati; Zohreh Rahimi; Gholamreza Bahrami
Journal:  Mol Biol Rep       Date:  2009-05-15       Impact factor: 2.316

9.  Osteoporosis syndrome in thalassaemia major: an overview.

Authors:  Meropi Toumba; Nicos Skordis
Journal:  J Osteoporos       Date:  2010-05-26

10.  The effect of whole body vibration therapy on bone density in patients with thalassemia: a pilot study.

Authors:  Ellen B Fung; Catherine A Gariepy; Aenor J Sawyer; Annie Higa; Elliott P Vichinsky
Journal:  Am J Hematol       Date:  2012-08-07       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.